Reframing Hyaluronidase in Aesthetic Medicine: From “Dissolving Filler” to “Modifying Filler”

June 30, 2026

Aesthetic Surgery Journal

Authors: Steven Harris, MBBCh, MSc , Steven Weiner, MD

Summary: Hyaluronidase is often described as “dissolving” dermal filler, but this term oversimplifies how the enzyme actually interacts with long-standing filler within living tissue. This article explains why hyaluronidase more accurately modifies a complex filler–tissue system rather than completely eliminating filler, and why clearer terminology improves patient understanding, clinical decision-making, and ethical practice in aesthetic medicine.

JOURNAL ARTICLE

Journals | June 30, 2026

A Real-World Study of Patient and Physician Satisfaction With Repeated AbobotulinumtoxinA Treatment of Glabellar Lines in Chinese Patients

AbobotulinumtoxinA (aboBoNT-A; Dysport®) is approved in China for treating glabellar lines (GLs) with fast onset of action (median: 2 days) and effectiveness up to 6 months (Chinese pivotal trial data), but real-world data remain limited. This study’s primary objective is to assess patient satisfaction following 3 cycles of aboBoNT-A treatment for moderate-to-severe GLs in a real-world setting.

Journals | June 30, 2026

Efficacy and Safety of a New Crosslinked Hyaluronic Acid Dermal Filler for Facial Volume Restoration: A Prospective Clinical Trial

Hyaluronic acid is commonly used as a dermal filler for aesthetic purposes. Crosslinking allows a better performance once injected into the skin. A new filler, known as BtHCROSS, has been developed using a novel crosslinking technology (SARE technology).

Journals | June 30, 2026

Therapeutic Efficacy and Safety of Recombinant Botulinum Toxin Type A for Moderate to Severe Glabellar Lines: A Randomized, Controlled, Double-blind, Phase III Trial in Chinese Adults

Conventional botulinum toxin type A (BoNT/A) products include non-therapeutic accessory proteins vary in composition and manufacturing processes, which may contribute to differences in purity and biochemical characteristics. YY001 (Retoxin®) is a novel recombinant BoNT/A manufactured via E. coli expression to reduce impurities, improve purity, and minimize immunogenic risk.

Journals | June 30, 2026

Orbicularis Oculi Toxin Injection for Treating Levator Palpebrae Superioris Weakness: Clinical Effect and Safety in a Cohort Study

Ptosis, the drooping of the upper eyelid caused by levator palpebrae superioris dysfunction, can impair vision and quality of life.

Journals | June 30, 2026

Ultrasound-Assisted Facial Autologous Fat Grafting: A Systematic Review of Perioperative Safety and Volumetric Outcomes

Abstract: High-frequency ultrasound (HFUS) is increasingly used to map facial vasculature and tissue planes, identify prior fillers, and objectively assess volume after autologous facial fat grafting (AFG), but its perioperative benefit has not been systematically synthesized.

Reframing Hyaluronidase in Aesthetic Medicine: From “Dissolving Filler” to “Modifying Filler”

Related Articles